ANAPTYSBIO, INC. Share-based Payment Arrangement, Decrease for Tax Withholding Obligation
ANAPTYSBIO, INC. (ANAB) reported Share-based Payment Arrangement, Decrease for Tax Withholding Obligation of $1.45 million for the 12-month period ending 2025-12-31, per its 10-KT filed 2026-09-21.
Financial Statements › Notes › Equity
us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation · last filed 2026-09-21
- ANAPTYSBIO, INC. share-based payment arrangement, decrease for tax withholding obligation for the quarter ending 2025-03-31 was $1.45M, a 80.66% decline year-over-year.
- ANAPTYSBIO, INC. share-based payment arrangement, decrease for tax withholding obligation for the quarter ending 2024-03-31 was $7.50M.
- ANAPTYSBIO, INC. share-based payment arrangement, decrease for tax withholding obligation for fiscal 2025 was $1.45M, a 80.66% decline from fiscal 2024.
- ANAPTYSBIO, INC. share-based payment arrangement, decrease for tax withholding obligation for fiscal 2024 was $7.50M.
| Period end | Share-based Payment Arrangement, Decrease for Tax Withholding Obligation 3 month | Share-based Payment Arrangement, Decrease for Tax Withholding Obligation 12 month |
|---|---|---|
| 2025-12-31 | $1.45M 10-KT · filed 2026-09-21 | |
| 2025-03-31 | $1.45M 10-Q · filed 2026-05-12 | |
| 2024-12-31 | $7.50M 10-KT · filed 2026-09-21 | |
| 2024-03-31 | $7.50M 10-Q · filed 2025-11-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |